Drugs / JRM-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02781922 | Jun 2016 → Dec 2028 expected | hypoplastic left heart syndrome, univentricular heart | Metcela Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Metcela Inc. | Regulatory Metcela Resumes Phase 3 Clinical Trials of Cell Product JRM-001 for Patients with Functional Single Ventricle metcela.com ↗
Metcela Inc. is pleased to announce that on January 31, 2025, we submitted and received acceptance for a clinical trial amendment notification to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, following a quality consultation. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JRM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781922 ↗ |
| Known as | Autologous cardiac stem cells | “Autologous cardiac stem cells (JRM-001)” NCT02781922 ↗ |